Arcutis Biotherapeutics, Inc. (ARQT)

NASDAQ • Healthcare

$25.16

-$0.12 (-0.5%)

Market closed

Last close at October 2, 2026 at 20:00 UTC

Open$25.64

Day Range$25.01 - $25.78

Avg. Volume (3M)3.6M

Market Cap$3.1B

P/E Ratio114.4

52 Week Range

$19.3$31.77

Next EarningsIn 23 daysOct 27, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$129.8M100%

Gross Profitminus cost of goods$118.9M92%

Operating Incomeminus R&D and overhead$16.4M13%

Net Incomeminus taxes and the rest$15M12%

In plain terms: out of every $100 in revenue, Arcutis Biotherapeutics, Inc. keeps $12 as net profit.

Fundamentals & Financials

Revenue (TTM)

$463.9M

Net Income (TTM)

$28.5M

EPS (TTM)

$0.22

ROA (TTM)

5.84%

Current Ratio

2.92

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+27.8%Q3 2025-$0.13

+160.0%Q4 2025$0.06

+333.3%Q1 2026$0.13

-350.0%Q2 2026-$0.09

+99.7%Q3 2026$0.11

Oct 27

in 23 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Next report — what to expect

Arcutis Biotherapeutics, Inc. (ARQT) is set to report on October 27, 2026. Wall Street is looking for consensus EPS of $0.17 on consensus revenue of $141.7 million. For trailing context, revenue grew +59.3% year over year last quarter. ARQT has beaten EPS in 7 of 8 most recent quarters.

View full earnings history

About Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. develops and markets therapies for skin-related diseases and operates as a biotechnology company listed on the NASDAQ under ARQT. In FY2025, the company generated $376.1 million in revenue. Formerly known as Arcutis, Inc., it focuses on dermatology products and pipeline programs built around inflammatory skin conditions.

Name

Arcutis Biotherapeutics, Inc.

CEO

Todd Franklin Watanabe

Website

www.arcutis.com

Industry

Healthcare

Year Founded

2016

Employees

354

Today's Snapshot

AI-generated

The day ended with ARQT 0.5% lower at 25.16, while its sector was flat.

Trading Volume

Below 10d avg (2.3M)

1.7M

vs S&P 500 Today

Underperforming Market

-1.29%

Updated: October 2, 2026 at 20:03 UTC

ARQT Headlines

FDA clears ZORYVE cream for children 2+

June 30, 2026

3 min read

View All News

Technical Indicators

0 Buy3 Neutral5 Sell

ARQT shows a pronounced technical vulnerability: the current price of 25.16 sits at or just below several short- and medium-term averages while failing to convincingly clear the 200-day area and the pivot near 25.65. Momentum is muted with neutral RSI and MACD readings, but OBV is negative, signaling distribution, and ATR is elevated at about 4.9%, reflecting higher price swings. ADX in the low-20s points to only moderate trend strength, yet the confluence of negative volume and weakness around moving averages favors sellers. Technical takeaway: strong sell, driven by distribution and weak positioning versus core averages.

All signals